Research library / Longevity compounds
CC Small or few human trials. Promising, not proven. How we grade →RCT (double-blind, placebo-controlled) · 50 healthy middle-aged adults, 4 weeks
Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial
D Denk, A Singh, H Kasler, D D'Amico, J Rey, L Alcober-Boquet et al. Nature Aging. 2025.
- In plain language
- 1,000 mg a day raised the share of naive-like CD8 T cells by 0.50 percentage points versus placebo, with other immune lab changes.
- Limits
- Lab measures only, no infections tracked; 4 weeks; funded by Amazentis, with employee authors.
- Which of our grades it feeds
- CC Small or few human trials. Promising, not proven. How we grade →Science summary: Urolithin A and mitochondria
- Source
- doi.org/10.1038/s43587-025-00996-x · PubMed 41174221 · Free full text
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.